ClinicalTrials.gg
TerminatedNCT06833281Updated Dec 18, 2025

Extension Study of Participants From SPG302-ALZ-101

A Phase 2 interventional study of SPG302 in Alzheimer's Disease, sponsored by Spinogenix. Terminated at 2 sites in Australia. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Spinogenix · Phase 2, Interventional, and Treatment

Why this study was terminated
patients treated on compassionate use program

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
45 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 177 studies in Alzheimer Disease with a site in Australia — 23 open to participants now, 42 under way, 18 of them phase 3. Alzheimer Disease · Australia.

Enrollment
164th of 168
12 · median 313
Started
2025
with 11 others
Phase 2
43 of 177
5 open now
Registered
156th of 177
by date

Among the 177 studies in Alzheimer Disease with a site in Australia, this one is the 164th largest by enrollment of the 168 interventional ones that give a count, is one of 12 that started in 2025, is one of 43 in phase 2, and was the 156th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

23 of the 177 studies in Alzheimer Disease with a site in Australia are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 45 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Alzheimer Disease with a site in Australia, or all of them as a file.
02

Study summary

This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALZ-101 with mild to moderate Alzheimer's Disease (AD)

Read the detailed description

This is an open-label extension study of SPG302-ALZ-101 to investigate the long-term safety, tolerability, and efficacy of SPG302 administered orally in participants with mild-to-moderate AD. Enrolled participants will continue at the dose they received at the end of the first trial, and will self-administer SPG302 orally every day for up to 52 weeks. Participants will have an in-person clinic visit every 3 months (± 3 days) and a monthly phone visit. An end of treatment visit will occur within 7 days of the last dose of SPG302. A final visit to collect safety data will be conducted up to 1 month (± 3 days) post last dose.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Alzheimer's Disease
  • synapse
  • neural connectivity
04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of mild to moderate AD
  • Clinical laboratory values within normal range or \< 1.5 times
  • of >2 years
  • Able and willing to provide written
  • Must have participated in all study activities of SPG302-ALZ-101, the parent study

Exclusion criteria

Exclusion Criteria:

Any physical or psychological condition that prohibits study completion

  • Known cardiac disease
  • Active or history of in the past 5 years
  • Serious infection that will not be resolved by first day of study intervention.
  • History of CNS event or diagnosis in the past 5 years.
  • Acute illness within 30 days of Day 1
  • History of suicidal behavior or suicidal ideation
  • History of chronic alcohol use or substance abuse in the last 5 years
  • , and/or positive
  • Vaccines within 14 days
  • Receipt of products within 30 days
  • Blood donation within 30 days
  • Pregnant or breastfeeding
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Open Label Extension

    Active SPG302 to be administered to adult participants with AD who completed initial study. Dose to be administered to be dose received during previous study.

    Drug: SPG302

Interventions

  • DrugSPG302

    small synthetic molecule

06

What researchers measure

Primary outcomes

  1. Treatment emergent adverse events and serious adverse events

    Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: Up to 52 weeks

  2. C-SSRS (Columbia Suicide Severity Rating Scale)

    Prospective suicidality assessment is performed using the Columbia-Suicide Severity Rating Scale (C-SSRS), a questionnaire to evaluate suicidal ideation and behavior. Answer "yes" on item 4 or 5 of the Suicidal Ideation section or "yes" on any item of the Suicidal Behavior section is considered positive. The suicidal behavior lethality sub-scale evaluates the level of actual or potential medical damage. The range is 0-25.Min is 0 and Max is 25.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Change in Mini-Mental State Examination (MMSE) from baseline to endpoint

    The Mini-Mental State Exam (MMSE) is a test of cognitive function. It includes tests of orientation, attention, memory, language and visual-spatial skills. The lower the score the greater the impairment. The range is 0-30. Min is 0 and Max is 30.

    Time frame: up to 52 weeks

  2. Change in Alzheimer's Disease Assessment Scale-Cog (ADAS-COG) total score from baseline to endpoint

    The ADAS-COG measures language and memory, focusing on cognitive and non-cognitive functioning. It evaluates word recall, naming of objects, word recognition, comprehension and word finding. The ADAS-COG is scored 0-70. Min is 0 and Max is 70. The higher the score the greater the impairment.

    Time frame: up to 52 weeks

  3. Quality of Life in Alzheimer's Disease (QOL-AD) from baseline to endpoint

    The QOL-AD is a test to evaluate the quality of life through a series of questions of ability to complete daily activities and tasks. A lower score indicates lower functional quality of life. Per question scored at 1-2-3-4. Overall range is Min is 13 and Max is 52.

    Time frame: up to 52 weeks

  4. Change in Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS - CGIC) from baseline to endpoint

    The ADCS - CGIC is a metric for clinical assessment of symptom severity. It consists of 2 parts. First a baseline evaluation of patient and caregiver is performed to collect necessary clinical information. The clinician will then conduct the second phase of the assessment after a specified time period, and changes in symptom severity are indicated on a seven-point scale. A higher scale indicates a worsening of symptoms. Range is 1-7. Min 1 and Max is 7.

    Time frame: up to 52 weeks

  5. Change in Alzheimer's Disease Clinical Dementia Rating Sum of Boxes (CDR-SB) from baseline to endpoint

    The CDR-SB is an interview performed with patient and caregiver, and will stage the severity of cognitive impairment. The higher the score, the greater the impairment. Range is 0-18. Min is 0 and Max is 18.

    Time frame: up to 52 weeks

  6. Change in Alzheimer's Disease Cooperative Study - Daily Living Inventory (ADCS-ADL) from baseline to endpoint.

    The ADCS-ADL is a metric to assess the ability to perform basic and instrumental activities of daily living. It is completed by a caregiver as a questionnaire or interview questions, and evaluates activities within the previous four weeks. Changes in symptom severity are indicated on a seven-point scale. A lower scale indicates greater impairment. Each question is 0-3. Total score is 78. Min is 0 and Max is 78.

    Time frame: up to 52 weeks

  7. Change in serum neurofilament light chain (NfL) in participants with AD from baseline to endpoint.

    To assess the effect of SPG302 on Neurofilament light (NfL), a protein elevated in AD. This will be measured in picometers/milliliter

    Time frame: up to 52 weeks

07

Study locations

2 sites
  • St. Vincent's Hospital
    Sydney, New South Wales 2010, Australia
  • Flinders Medical Center
    Adelaide, South Australia 5000, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Jul 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2025
First posted
Feb 18, 2025
StartActual
Mar 25, 2025
Primary completionActual
Jul 30, 2025
CompletionActual
Oct 9, 2025
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06833281
Lead sponsor
Spinogenix
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Mar 25, 2025
Primary completion
Jul 30, 2025
Completion
Oct 9, 2025
Last update
Dec 18, 2025

Study contacts

Lauren Priest, MBBS
principal investigator · Flinders Medical Center, Adelaide, SA, Australia
Brew Brew, MBBS, MD, DSC
principal investigator · St Vincents Hospital, Sydney, NSW, Australia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SPG-302

Start the discussion